As clinical research advances, PARP inhibitors have not been limited to managing PC patients with BRCA1/2 gene mutation and have been implemented in a wider range of patients with homologous recombination repair (HRR)-associated gene mutation. This evidence concerns the gene BRCA1 and pachyonychia congenita.